What the authors are telling us is that much of the cancer information on social media concerning the four most common cancers (breast, lung, colon, and prostate), is wrong. In fact, about one third of the 200 articles reviewed contained misinformation and 30.5% contained harmful information. And these were
Lilly’s anti-SARS-CoV-2 combination of antibodies bamlanivimab and etesevimab joins Regeneron’s REGEN-COV, a combinations of the monoclonal antibodies casirivimab and imdevimab, as another lifesaving option for COVID-19 post exposure prophylaxis.
At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from a phase 3 clinical trial testing fixed-duration
While not directly related to CLL, this second FDA approved indication is another reason to anticipate that zanubrutinib will soon be an approved option for chronic lymphocytic leukemia (CLL) patients. And that is good news for us. The more treatment choices we have, the better.